Table 3 Sensitivities and specificities of different strategies for Lynch Syndrome.
Methods | Lynch | Sporadic | Sensitivities % (95% Confidence Interval) | Specificities % (95% Confidence Interval) | PPVs % (95% Confidence Interval) | NPVs % (95% Confidence Interval) |
|---|---|---|---|---|---|---|
BRAF wt | 23 | 80 | 100% (82.2–100%) | 7.0% (2.9–15.1%) | 22.3% (15.0–31.8%) | 100% (51.7–100%) |
BRAF mt | 0 | 6 | ||||
MLH1 methylation (−) | 22 | 47 | 95.7% (76.0–99.8%) | 45.3% (34.7–56.4%) | 31.9% (21.5–44.3%) | 97.5% (85.3–99.9%) |
MLH1 methylation (+) | 1 | 39 | ||||
BRAF wt + MLH1 methylation (−) | 22 | 46 | 95.7% (76.0–99.8%) | 47.7% (36.9–58.7%) | 32.8% (22.1–45.5%) | 97.6% (85.9–99.9%) |
BRAF mt or/and MLH1 methylation (+) | 1 | 40 | ||||
RBC (−) + MLH1 methylation (−) | 23 | 59 | 100% (82.2–100%) | 29.1% (20.0–40.0%) | 27.4% (18.5–38.4%) | 100% (83.4–100%) |
RBC (+) or MLH1 methylation (+) | 0 | 27 |
